Cancer Drug Parity Act of 2025

# Cancer Drug Parity Act of 2025 - Summary **What the Bill Would Do** The Cancer Drug Parity Act of 2025 (HR 4101) aims to ensure equal treatment of cancer medications under health insurance plans. While the full legislative text isn't available in your summary, bills with this title typically address disparities in how insurance companies cover different types of cancer drugs—such as ensuring oral cancer medications (pills) are covered the same way as intravenous cancer treatments (injections). The goal is usually to prevent patients from facing higher out-of-pocket costs for certain cancer treatments simply because of how the drug is administered. **Who It Affects** This legislation would primarily impact cancer patients, health insurance companies, and employers who offer health plans.

It could affect how insurance plans structure their drug coverage and patient cost-sharing requirements going forward. **Current Status** As of now, HR 4101 remains in committee and has not yet advanced for a full vote in the House of Representatives. The bill was introduced by Representative Glenn Grothman (R-WI). Further details about specific provisions would require reviewing the actual bill text, which wasn't included in the information provided.